Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial

J Invest Dermatol. 2012 Oct;132(10):2466-2469. doi: 10.1038/jid.2012.163. Epub 2012 May 24.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Anti-Idiotypic / administration & dosage
  • Antibodies, Anti-Idiotypic / adverse effects
  • Antibodies, Anti-Idiotypic / therapeutic use*
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Injections, Subcutaneous
  • Male
  • Middle Aged
  • Psoriasis / drug therapy*
  • Psoriasis / immunology
  • Receptors, Interleukin-17 / immunology*
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antibodies, Anti-Idiotypic
  • Receptors, Interleukin-17

Associated data

  • ClinicalTrials.gov/NCT00867100